NASDAQ · BLTE
Belite Bio, Inc
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for BLTE: Nov 9, 2026
Belite Bio, Inc American Depositary Shares is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.73. The reported EPS for the same quarter last year was $-0.65.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.73 | $-0.67 | $-0.84 | 3 |
| Dec 2026 | $-0.79 | $-0.70 | $-0.87 | 2 |
| Mar 2027 | $3.69 | $3.69 | $3.69 | 1 |
| Jun 2027 | $-0.47 | $-0.47 | $-0.47 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · Fintel · MarketBeat- RTTNews · Oct 19, 12:46 PM EDTBelite Bio Elevates Nasdaq Listing As Company Advances Retinal Disease Pipeline(RTTNews) – Belite Bio, Inc. (BLTE), a clinical-stage drug development company focused on degenerative retinal diseases, announced that Nasdaq approved the transfer of its securities from the Nasdaq Capital Market to the Nasdaq Global Select Market, effective October 19, 2026.
- RTTNews · Oct 15, 12:30 AM EDTBelite Bio Files Regulatory Applications For Tinlarebant In Singapore, UK, Switzerland(RTTNews) – Belite Bio, Inc. (BLTE), a clinical-stage drug development company focused on degenerative retinal diseases, announced Marketing Authorisation Application (MAA) submissions to the regulatory authorities in Singapore, the United Kingdom, and Switzerland for tinlarebant
- RTTNews · Sep 29, 10:23 AM EDTBelite Bio To Present Tinlarebant Data At Euretina(RTTNews) – Tuesday, Belite Bio (BLTE) said it will present data from its retinal disease programs at two upcoming medical conferences in Vienna, including topline Phase 3 DRAGON study results for tinlarebant in adolescent Stargardt disease.
- Zacks · Sep 9, 9:55 AM EDTBelite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden CrossWhen a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
- RTTNews · Sep 8, 6:37 AM EDTBelite Bio Announces NDA Submission In Japan For Tinlarebant Under Sakigake Designation(RTTNews) – Belite Bio (BLTE) announced the submission of a New Drug Application to the Ministry of Health, Labour, and Welfare in Japan for tinlarebant in Stargardt disease type 1. Tinlarebant has been designated a SAKIGAKE pharmaceutical product for accelerated review and the N
- Fintel · Sep 6, 3:19 AM EDTCanaccord Genuity Initiates Coverage of Belite Bio, Inc – Depositary Receipt at BuyFintel reports that on September 4, 2026, Canaccord Genuity initiated coverage of Belite Bio, Inc – Depositary Receipt (NASDAQCM:BLTE) with a Buy recommendation. Prior to this action, the stock closed at $171.09 on September 3, 2026, and subsequently closed at $193.61 on Septembe
- MarketBeat · Sep 3, 12:01 AM EDTBelite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease3 Lesser-Known Healthcare Names With Major Upside in StoreBelite Bio (NASDAQ:BLTE) said the U.S. Food and Drug Administration has accepted its new drug application for tinlarebant as a treatment for Stargardt disease type 1, granted the application priority review and set a Feb.
- MarketBeat · Aug 13, 6:04 PM EDTBelite Bio Q2 Earnings Call Highlights3 Lesser-Known Healthcare Names With Major Upside in StoreBelite Bio (NASDAQ:BLTE) said the U.S. Food and Drug Administration has accepted its New Drug Application for tinlarebant, an investigational treatment for Stargardt disease, and granted the application priority review. Th
- NASDAQ.com · Aug 13, 2:00 PM EDTAfter-Hours Earnings Report for August 13, 2026 : AMAT, BAP, BLTE, CELC, HTFL, NKTR, DLO, STNE, TMC, GLOB, JCAP, ETONThe following companies are expected to report earnings after hours on 08/13/2026. Visit our Earnings Calendar for a full list of expected earnings releases.Applied Materials, Inc. (AMAT)is reporting for the quarter ending July 31, 2026. The electric company company's consensus
- RTTNews · Aug 13, 5:42 AM EDTBelite Bio Q2 Net Loss Widens; FDA Sets PDUFA Date For Tinlarebant In February 2027(RTTNews) – Belite Bio, Inc (BLTE), a clinical-stage drug development company, announced its financial results for the second quarter, reflecting a wider net loss.
- Zacks · Aug 12, 8:54 AM EDTBLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDABelite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.
- MarketBeat · Jul 22, 5:02 PM EDTBelite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases3 Lesser-Known Healthcare Names With Major Upside in StorePanelists at the H.C. Wainwright Sixth Annual Ophthalmology Virtual Conference said investigational therapies for inherited retinal disorders could begin to reshape treatment options for Stargardt disease and retinitis pig
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Belite Bio, Inc from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.